Exploration of the Binding Modes of Toll-Like Receptor 4 Competitive Inhibitors: A Combined Ligand-Based and Target-Based Approach

被引:2
|
作者
Dang, Wen [1 ]
Meng, Churen [1 ]
Wang, Jian [2 ]
Zhou, Di [2 ]
Chen, Gang [2 ]
Li, Ning [2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab TCM Mat Basis Study & Innovat Drug Dev She, Shenyang 110016, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Key Lab Struct, Based Drug Design & Discovery Minist Educ, 103 Wenhua Rd, Shenyang 110016, Peoples R China
基金
中国国家自然科学基金;
关键词
TLR4; MD-2; pharmacophores; competitive inhibitors; blind docking; MOLECULAR-DYNAMICS; INNATE IMMUNITY; TLR4; DOCKING;
D O I
10.1002/cmdc.202200690
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interactions of Toll-like receptor 4 (TLR4) with competitive inhibitors were investigated by a combined ligand-based and target-based approach. Firstly, the ligand-based pharmacophore model of the reported TLR4 inhibitors was constructed by utilizing the common feature method, which included three hydrophobic groups and a hydrogen bond receptor. The Schrodinger software suite glide module was used to dock inhibitors with proteins and verify the importance of these four interaction points from the target level. Then, molecular dynamics, alanine scanning mutagenesis, and binding free energy calculation were used to identify the key amino acids in the binding mode. In addition, blind docking proved that the TLR4 inhibitor does not bind to TLR4 itself like other TLR family proteins. Based on this, we also screened a class of sesquiterpene coumarins which possibly have TLR4 inhibitory activity and will conduct a detailed study later. Together, this study revealed the interactions between TLR4 protein and its competitive inhibitors, which shed light on better access for developing its novel inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Rigorous Incorporation of Tautomers, Ionization Species, and Different Binding Modes into Ligand-Based and Receptor-Based 3D-QSAR Methods
    Natesan, Senthil
    Balaz, Stefan
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (23) : 4316 - 4322
  • [42] Toll-like Receptor Ligand-Based Vaccine Adjuvants Require Intact MyD88 Signaling in Antigen-Presenting Cells for Germinal Center Formation and Antibody Production
    Mosaheb, Munir M.
    Reiser, Michael L.
    Wetzler, Lee M.
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [43] Toll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis
    Wang, Xiao-Qin
    Zhang, Kui
    Xiong, Ding
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2013, 38 (03) : 380 - 387
  • [44] Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant
    Syntin, Patrick
    Piras-Douce, Fabienne
    Dalencon, Francois
    Garinot, Marie
    Haensler, Jean
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2023, 460
  • [45] Impaired Interferon-Alpha Production by Plasmacytoid Dendritic Cells after Cord Blood Transplantation in Children: Implication for Post-transplantation Toll-Like Receptor Ligand-Based Immunotherapy
    Charrier, Emily
    Cordeiro, Paulo
    Brito, Rose-Marie
    Harnois, Michael
    Mezziani, Samira
    Herblot, Sabine
    Le Deist, Francoise
    Duval, Michel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (10) : 1501 - 1507
  • [46] Structure-Activity Relationship in Monosaccharide-Based Toll-Like Receptor 4 (TLR4) Antagonists
    Facchini, Fabio A.
    Zaffaroni, Lenny
    Minotti, Alberto
    Rapisarda, Silvia
    Calabrese, Valentina
    Forcella, Matilde
    Fusi, Paola
    Airoldi, Cristina
    Ciaramelli, Carlotta
    Billod, Jean-Marc
    Schromm, Andra B.
    Braun, Harald
    Palmer, Charys
    Beyaert, Rudi
    Lapenta, Fabio
    Jerala, Roman
    Pirianov, Grisha
    Martin-Santamaria, Sonsoles
    Peri, Francesco
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 2895 - 2909
  • [47] Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy
    Wu, Yi
    Zhang, Bo
    Dong, Xiaowu
    Ma, Shenglin
    Hu, Shengquan
    LETTERS IN DRUG DESIGN & DISCOVERY, 2022, 19 (07) : 627 - 636
  • [48] Searching for a reliable orientation of ligands in their binding site: Comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors
    Gratteri, P
    Bonaccini, C
    Melani, F
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) : 1657 - 1665
  • [49] Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay
    Knoepfel, Thomas
    Nimsgern, Pierre
    Jacquier, Sebastien
    Bourrel, Marjorie
    Vangrevelinghe, Eric
    Glatthar, Ralf
    Behnke, Dirk
    Alper, Phil B.
    Michellys, Pierre-Yves
    Deane, Jonathan
    Junt, Tobias
    Zipfel, Geraldine
    Limonta, Sarah
    Hawtin, Stuart
    Andre, Cedric
    Boulay, Thomas
    Loetscher, Pius
    Faller, Michael
    Blank, Jutta
    Feifel, Roland
    Betschart, Claudia
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (15) : 8276 - 8295
  • [50] An integrated digital microfluidic electrochemical impedimetric lipopolysaccharide sensor based on toll-like receptor-4 protein
    de Campos R.P.S.
    Aggarwal D.
    Chan N.W.C.
    Jemere A.B.
    Biosensors and Bioelectronics: X, 2024, 16